Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04935138
Other study ID # CD20-011
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date June 1, 2021
Est. completion date December 31, 2022

Study information

Verified date November 2023
Source Quest Diagnostics-Nichols Insitute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study assesses the accuracy of cell-free DNA (cfDNA) analysis in detecting whole chromosomal aneuploidies from maternal plasma of patients with early, missed miscarriage.


Recruitment information / eligibility

Status Terminated
Enrollment 78
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - 5-20 weeks of gestation by ultrasound - Miscarriage diagnosed by ultrasound - Pregnancy tissue still present in utero, including an empty sac, and not completely expelled Exclusion Criteria: - Maternal age < 18 years - No visible pregnancy tissue on ultrasound - Multiple fetal gestation (> than singleton) - Pregnancy was conceived using in vitro fertilization (IVF) with preimplantation genetic testing for aneuploidy (PGT-A) performed on the transferred embryo - No microarray testing is planned on the product of conception - Previous normal non-invasive prenatal testing (NIPT) or diagnostic testing (chorionic villous sampling or amniocentesis) in the current pregnancy - Patient unable to provide consent

Study Design


Intervention

Genetic:
cfDNA analysis
sequencing data from cfDNA analysis

Locations

Country Name City State
United States Quest Diagnostics San Juan Capistrano California

Sponsors (2)

Lead Sponsor Collaborator
Quest Diagnostics-Nichols Insitute Illumina, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (3)

Barisic I, Zergollern L, Muzinic D, Hitrec V. Risk estimates for balanced reciprocal translocation carriers--prenatal diagnosis experience. Clin Genet. 1996 Mar;49(3):145-51. doi: 10.1111/j.1399-0004.1996.tb03274.x. — View Citation

ESHRE. European Society of Human Reproduction and Embryology guideline: recurrent pregnancy loss. Human Reproduction Open 2018: 1-12.

Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012 Nov;98(5):1103-11. doi: 10.1016/j.fertnstert.2012.06.048. Epub 2012 Jul 24. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary microarray analysis of products of conception (POC) chromosome anomalies 7 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04595760 - Factors Influencing Fertility or Pregnancy Health
Completed NCT01132924 - A Follow-up of the Early Pregnancy Study Cohort.
Recruiting NCT05880381 - Virtual Reality for Coping With Involuntary Early Pregnancy Loss N/A
Completed NCT04410029 - Evaluation of a Decision Aid for Early Pregnancy Loss N/A
Not yet recruiting NCT06452719 - Letrozole and Misoprostol for Early Pregnancy Loss Management: A Prospective Pilot Cohort Study Phase 2
Recruiting NCT04738370 - Assessment of Biomarkers in Pregnancy on Unknown Location and Ectopic Pregnancy
Not yet recruiting NCT06309927 - Operative Hysteroscopy Versus Suction Curettage for Surgical Termination of Early Pregnancy Loss (Miscarriage) N/A